These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. [Prescribing patterns of rofecoxib in the primary care setting: results of a French survey]. Bannwarth B; Logeart I; Vergult G Rev Med Interne; 2004 Oct; 25(10):710-4. PubMed ID: 15471596 [TBL] [Abstract][Full Text] [Related]
48. [Is there a future for COX-2 inhibitors?]. Yodfat Y Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272 [TBL] [Abstract][Full Text] [Related]
50. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Spiegel BM; Targownik L; Dulai GS; Gralnek IM Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551 [TBL] [Abstract][Full Text] [Related]
51. [New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]. Berenbaum F Ann Med Interne (Paris); 2002 Feb; 153(1):25-33. PubMed ID: 11994687 [TBL] [Abstract][Full Text] [Related]
52. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Brinker A; Goldkind L; Bonnel R; Beitz J Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714 [TBL] [Abstract][Full Text] [Related]
53. Rofecoxib-induced pseudoporphyria. Markus R; Reddick ME; Rubenstein MC J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522 [No Abstract] [Full Text] [Related]
54. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
55. [The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria]. Lüth P; Herold M; Mur E Wien Med Wochenschr; 2005 May; 155(9-10):211-6. PubMed ID: 15999628 [TBL] [Abstract][Full Text] [Related]